Michael McMullen
Psychiatric/Mental Health · New Castle, PANPI 1528485026
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 82.0% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $4,164 and has fallen 91.8% since, to $343 in 2025. Among psychiatric/mental health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $55.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- Otsuka America Pharmaceutical, Inc.$432
- Lundbeck LLC$377
- Takeda Pharmaceuticals U.S.A., Inc.$279
- Indivior Inc.$244
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$203
- plus $419 from 8 others
What the payments were for
- Speaking & faculty fees$6,05056%
- Travel & lodging$1,59415%
- Food & beverage$3,18329%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 79 | $8,920 |
| Otsuka America Pharmaceutical, Inc. | 24 | $432 |
| Lundbeck LLC | 23 | $377 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $279 |
| Indivior Inc. | 14 | $244 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $203 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $158 |
| Vanda Pharmaceuticals Inc. | 3 | $70 |
| Teva Pharmaceuticals USA, Inc. | 3 | $59 |
| Alkermes, Inc. | 3 | $48 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
| Abbott | 1 | $20 |
| Almatica Pharma LLC | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$7,618
How this compares
$10,874 in reported general payments places this provider in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
See all psychiatric/mental health providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 79 | $112,520 |
| TrintellixVortioxetine Hydrobromide | 73 | $40,415 |
| Adderall XrDextroamphetamine/Amphetamine | 38 | $12,169 |
| AdderallDextroamphetamine/Amphetamine | 25 | $7,329 |
| Aripiprazole | 263 | $7,308 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 277 | $5,330 |
| Lurasidone Hcl | 29 | $4,085 |
| Bupropion XlBupropion Hcl | 125 | $3,220 |
| Alprazolam | 461 | $2,754 |
| Vilazodone Hcl | 20 | $2,145 |
| Fluvoxamine Maleate | 112 | $2,083 |
| Prazosin Hcl | 125 | $1,706 |
| Duloxetine Hcl | 74 | $1,488 |
| Clonazepam | 124 | $1,356 |
| Methylphenidate ErMethylphenidate Hcl | 23 | $1,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $432 | $112,52079 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Adderall | $279 | $47,74498 claims |
| Almatica Pharma LLCSertraline Hcl | $15 | $1,221165 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
Other psychiatric/mental health in New Castle
- Jonathan FellionNew Castle$16K
- Terri SharoNew Castle$13K
- Lisa DewittNew Castle$11K
- Shelby HitesNew Castle$9K
- Kimberly GarciaAllentown$573K
- Cortney SmithWashington$227K
- Britney KeplerPittsburgh$158K
- Kirstyn KamegBethel Park$136K
- Anna DipietroDowningtown$131K
- Deena MasciocchiLanghorne$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.